Pfizer Inc.

Pfizer Inc.

PFE

$27.93

Updated: 23/09/2026, 09:42:11

Market Cap
$159.19B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Stock valuation chart
One-year closing share-price history for PFE
Company Profile

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

USD
NYSE
CEO: Albert Bourla
Employees: 75,000
https://www.pfizer.com
Asset Summaries
Latest generated summaries for PFE

No summaries found.

Detailed business
The latest official filing is available; structured extraction is pending.
PFE-10-k-fy2025.html5.0 MBtext/htmlENFiled 26/02/2026Period ended 31/12/2025

The original document can be viewed now. Detailed facts and exposure relationships will appear after the separate extraction job completes.

Full company information
Latest profile, trading, valuation, and identifier data stored for PFE.
Share price
$27.93
Market cap
$159.19B
Exchange
NYSE
Currency
USD
CEO
Albert Bourla
Employees
75,000
IPO date
01/06/1972
Beta
0.299
Last dividend
$0.00
Day range
$27.50 – $27.99
52-week range
$23.58 – $29.21
1-day performance
0.68%
1-year performance
18.45%
Current drawdown (1Y)
-4.38%
CIK
0000078003
CUSIP
717081103
ISIN
US7170811035
Created
07/12/2025, 05:43:26
Last update
23/09/2026, 09:42:11

Track Pfizer Inc. with an AI analyst

See which prediction-market events move PFE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to PFE from your Railway `news_articles` table.

This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It's a Flawless Safe-Haven for Retirees

24/7 Wall Street • STOCK • 11/06/2026, 16:26:07

A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25

24/7 Wall Street • STOCK • 11/06/2026, 16:23:39

Prediction: Pfizer Stock Will Double on This Date

24/7 Wall Street • STOCK • 10/06/2026, 04:06:09

RBC Capital Upgrades Pfizer (NYSE: PFE) Amid Positive Drug Developments

Market Data • Market Data • 10/06/2026, 00:18:39

Amneal and Pfizer GLP-1 Deal: New Growth Lever?

Zacks Investment Research • STOCK • 09/06/2026, 15:20:32

Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 08/06/2026, 13:48:30

Wall Street Breakfast Podcast: Pfizer Chases Monthly Edge

Seeking Alpha • STOCK • 08/06/2026, 09:04:32

US FDA approves Pfizer's bleeding disorder drug for children

Reuters • STOCK • 08/06/2026, 08:49:21

3 Dividend Stocks to Buy Hand Over Fist in June

The Motley Fool • STOCK • 07/06/2026, 03:30:00

Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.

The Motley Fool • STOCK • 06/06/2026, 15:32:00

Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems

The Motley Fool • STOCK • 06/06/2026, 14:15:00

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Reuters • STOCK • 06/06/2026, 11:06:33